

Special Issue

Advances in Adrenocortical Carcinoma Research: Diagnosis, Treatment and Prognosis

Message from the Guest Editor

Adrenocortical carcinoma (ACC) is a rare aggressive tumor. Surgery represents the treatment of choice. Mitotane is used in adjuvant settings in high-risk patients (stage III and Ki67>10%) and in palliative case in association with EDP (etoposide-doxorubicin-cisplatin). Target therapies and immunotherapies do not demonstrate a real efficacy in ACC patients. Considering the poor prognosis, new strategies are necessary. This Special Issue will focus on future curative options in ACC patients at clinical and preclinical levels, considering possible diagnostic, therapeutic, and prognostic innovations.

Guest Editor

Dr. Letizia Canu

Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy

Deadline for manuscript submissions

closed (31 July 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/108290

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)